PAOG Signals BUY - CBD Pharma Development Backed US Patent
April 12 2021 - 8:43AM
InvestorsHub NewsWire
April 12, 2021 -- InvestorsHub NewsWire -- via AmericanBulls.com/PAOG
PAO Group, Inc.
(USOTC:
PAOG)
Our system’s recommendation today is
to BUY.
The BULLISH
ENGULFING pattern
finally received a confirmation because the prices crossed above
the confirmation level which was at 0.0078, and our valid average
buying price stands now at 0.0080.
Let’s jump on our white horses and go for a bullish ride. The
bullish pattern that was previously identified is finally confirmed
and a BUY signal is
generated. The market is telling you about a new profit. Do not
miss this bullish opportunity.
Recent News From PAOG published on Yahoo.Finance.com/PAOG
PAOG Advances CBD Pharmaceutical Developments Backed By
US Patent
Sandusky, Ohio--(Newsfile Corp. - April 8, 2021) - PAO Group, Inc.
(OTC
Pink: PAOG) today announced a management update on the
company's ongoing CBD Pharmaceutical Development Program progress
scheduled to be released next week on Tuesday, April 13, 2021.
Last year, PAOG acquired RespRx from Kali-Extracts, Inc.
(OTC
Pink: KALY). RespRx is a CBD treatment under development for
Chronic Obstructive Pulmonary Disorder (COPD) derived from a
patented cannabis extraction method - U.S. Patent No. 9,199,960
entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT
MATERIALS INCLUDING THE CANNABIS PLANT."
PAOG is working with Veristat, a
contract research organization (CRO), dedicated to the clinical
advance of therapies and treatments through regulatory approval.
PAOG anticipates soon announcing new breakthroughs in its CBD
RespRx pharmaceutical research.
Last month, PAOG released a comprehensive update on
its CBD
Nutraceutical Development Program with the first
PAOG CBD Nutraceutical products, packaged by Alkame Holdings, Inc.
(OTC
Pink: ALKM), expected to come to market before the end of this
year marketed through North American Cannabis Holdings, Inc.
(OTC
Pink: USMJ). Next week, on Tuesday, PAOG will release a similar
update on its CBD Pharmaceutical Development Program.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news
release may contain forward-looking information within the meaning
of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under
the Securities Exchange Act of 1934, and are subject to the safe
harbor created by those rules. All statements, other than
statements of fact, included in this release, including, without
limitation, statements regarding potential future plans and
objectives of the company are forward-looking statements that
involve risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and actual results and
future events could differ materially from those anticipated in
such statements. Technical complications, which may arise, could
prevent the prompt implementation of any strategically significant
plan(s) outlined above. The Company undertakes no duty to revise or
update any forward-looking statements to reflect events or
circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
SOURCE:
AmericanBulls.com/PAOG
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Oct 2023 to Oct 2024